7 results about "Tumor hypoxia" patented technology

The application discloses a kind of lipid droplet targeted NIR-I photothermal agent and its application in hypoxic tumor treatment, belong to the technical field of photothermal therapy.The NIR-I photothermal agent of the application is a kind of organic photothermal material based on donor-acceptor structure, with strong electron-deficient and rigid planar structure dithiophene pyrrolone sub benzodifuran diketone (BTPDBDF) as acceptor unit, respectively with triphenylamine and tetraphenyl ethylene as donor unit, with strong intramolecular charge transfer, absorption spectrum reaches near infrared region one.Simultaneously, the material is prepared into water-soluble nanoparticles by nano precipitation method, and the biocompatibility and targeting are improved.The nano preparation has the ability of specific targeting cell lipid droplet, and shows significant heating performance and high photothermal conversion efficiency under 808 nm laser irradiation, and shows good near-infrared light capturing capacity, so as to facilitate effective photothermal therapy under the condition of tumor hypoxia.

The present application relates to the technical field of microorganism, specifically relates to an engineering bacteria, a construction method, an engineering bacteria medicine delivery system and purposes thereof, and provides an engineering bacteria, which comprises at least one coding gene A capable of coding interferon IFN-gamma; the chassis bacteria of the engineering bacteria is Clostridium butyricum; since Clostridium butyricum is an anaerobic gram-positive bacteria, its spores can resist adverse environment and enter the intestinal cavity through gastric juice, and in view of the hypoxic microenvironment of tumor, the engineering bacteria Clostridium butyricum spores of the present application can target the hypoxic microenvironment of tumor, and further can mildly express IFN-gamma, the expression amount is stable, and it is more safe and reliable.

The application discloses an FBXO48 inhibitor which can effectively enhance the curative effect of paclitaxel under lung cancer hypoxia, and particularly relates to a combined use of an FBXO48 inhibitor (BC1618) and a chemotherapeutic drug (paclitaxel) and application of the combined use in preparation of a drug for treating hypoxia-driven drug-resistant tumors. The application discloses for the first time that FBXO48 up-regulates CA9 and glycolysis pathway through a CAMKK2-pAMPK alpha-HIF1 alpha signal axis, and mediates drug resistance of tumor cells to chemotherapeutic drugs such as paclitaxel under hypoxia. The FBXO48 inhibitor (BC1618) can restore the sensitivity of tumor cells to chemotherapeutic drugs by blocking the signal axis, and shows a significant synergistic effect in patient-derived tumor organoids and mouse xenograft models. The application provides a brand-new combined treatment strategy for overcoming the chemotherapeutic resistance caused by the tumor hypoxic microenvironment.

This invention relates to the field of cell culture technology, and discloses a method for culturing NK cells and its applications. When NK cells enter a hypoxic environment, not only do their cytotoxic activity and proliferative capacity rapidly decline, but they also experience metabolic disorders such as impaired mitochondrial function, insufficient ATP production, and abnormal accumulation of reactive oxygen species (ROS), leading to functional failure and limiting their application in tumor therapy. Existing technologies mainly rely on constant or single-stage hypoxia induction, failing to improve the insufficient hypoxia adaptation of NK cells at the metabolic level. Therefore, this invention provides a method that uses repeated acclimatization culture with gradually decreasing oxygen concentration to allow NK cells to gradually adapt to the metabolic demands of a hypoxic environment. NK cells cultured using this method exhibit a more stable metabolic state and superior cytotoxic activity in a hypoxic environment, significantly enhancing their anti-tumor efficacy and solving the problem of metabolic imbalance and rapid functional loss of NK cells in the hypoxic tumor microenvironment in existing technologies.

The application belongs to the technical field of biological medicine and photodynamic therapy, and particularly relates to an aggregation-induced emission photosensitizer with tumor hypoxia relief function and a preparation method and application thereof. The photosensitizer is MeTCP-F, which uses methoxy-modified triphenylamine as an electron donor, benzindole as an electron acceptor, and thiophene as a pi bridge to form a D-pi-A structure, and is connected with a perfluorinated compound through an ester bond; and the MeTCP-F NPs are prepared by using CH3-PEG-DSPE through a nano precipitation method. The photosensitizer has near-infrared fluorescence imaging, active oxygen generation and oxygen carrying capacity, can relieve tumor hypoxia, cooperatively realize the generation of type I and type II active oxygen, and improve the photodynamic therapy effect. The MeTCP-F NPs have good water solubility and high biocompatibility, can be enriched in tumor tissues through the EPR effect, can realize efficient tumor killing under the guidance of near-infrared imaging, have low systemic toxicity, and have application value in the preparation of anti-tumor photodynamic therapy drugs.

This invention discloses an ultrasound-responsive Pickering-like emulsion and its application in the preparation of tumor therapeutic agents, relating to the field of tumor therapeutic nanomaterials. The emulsion consists of oxygen-carrying perfluorohexane droplets and copper-coordinated 1 / 4-carboxyphenyl porphyrin nanoparticles, wherein the nanoparticles act as colloidal surfactants, armoring the surface of the perfluorohexane droplets to form a Pickering-like emulsion. The preparation method includes: coordinating 1 / 4-carboxyphenyl porphyrin with copper chloride and co-assembling it with Pluronic F127 to obtain FTC NPs; then emulsifying perfluorohexane with the FTC NPs to obtain PFTC EMs, which can be further oxygen-saturated to obtain an oxygen-carrying emulsion. Under ultrasound, the emulsion undergoes responsive disintegration and simultaneously releases oxygen and FTC NPs, which can both deplete glutathione and alleviate tumor hypoxia, and promote the generation of reactive oxygen species and Cu. + Induced copper death, thereby reshaping the tumor microenvironment and enhancing the synergistic antitumor effect of sonodynamics / copper death.

This invention belongs to the interdisciplinary field of biomedicine and nanomaterials, specifically disclosing an engineered cyanobacteria-nanodiamond composite, its preparation method, and its applications. The composite includes genetically modified engineered cyanobacteria capable of stably synthesizing and secreting photosensitizers, and red fluorescent nanodiamonds containing nitrogen-vacancy centers that emit fluorescence at 600-750 nm under ≥532 nm light excitation. The nanodiamonds are loaded onto the surface of the cyanobacteria or into the extracellular matrix. This invention integrates the in-situ oxygen production / photosensitizer production function of cyanobacteria with the deep fluorescence emission characteristics of nanodiamonds, synergistically alleviating tumor hypoxia and enhancing deep photodynamic therapy. It exhibits good biocompatibility, controllable preparation, and broad application prospects in the treatment of solid tumors.